Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Akorn, Inc. to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference.


BUFFALO GROVE Buffalo Grove

A village of northeast Illinois, a suburb of Chicago. Population: 43,300.
, Ill. -- Akorn, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: AKRX) today announced that Arthur S. Przybyl, president and chief executive officer, will be presenting at the CIBC World Markets CIBC World Markets is the investment banking division of the Canadian Imperial Bank of Commerce. It helps governments, large companies, and other large institutions obtain capital and credit and is a primary dealer in U.S. Treasury securities.  Annual Biotechnology & Specialty Pharmaceuticals Conference. The presentation is scheduled for 2:30 p.m. Eastern Time on Thursday, April 12, 2007 at the Millennium Broadway Hotel located in New York City New York City: see New York, city.
New York City

City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S.
.

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey Somerset is a census-designated place and unincorporated area located at the eastermost section within Franklin Township, in Somerset County, New Jersey. As of the United States 2000 Census, the CDP population was 23,040. Somerset housed one of the first Marconi Wireless Stations.  and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
 Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings All actions that are authorized or sanctioned by law and instituted in a court or a tribunal for the acquisition of rights or the enforcement of remedies. , and financial results.

Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock.

Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K Form 10-K

A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.


Form 10-K

See 10-K.
, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Such factors include, but are not limited to, risks and uncertainties relating to the resolution of the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 compliance issues at our Decatur, Illinois manufacturing facility. Other factors besides those listed there could also adversely affect our results.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 4, 2007
Words:479
Previous Article:Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical...
Next Article:P.F. Chang's First Quarter Revenues Grow 16%.
Topics:



Related Articles
Akorn, Inc. Names Marshall L. Goodwin as Vice President, Global Quality and Regulatory Compliance.
Akorn, Inc. Names Russell A. Gall, Vice-President and General Manager, Decatur Operations.
Akorn, Inc. Signs a Letter of Intent with Cipla, Ltd. to Develop and Supply an Oral Anti-Infective ANDA Drug Product.
Akorn, Inc. and Cipla, Ltd. Announce the Signing of an Exclusive Drug Manufacturing and Supply Agreement For an Oral Anti-Infective ANDA Drug Product.
Akorn, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference.
Akorn, Inc. Signs a Definitive Exclusive Development and Supply Agreement with Sofgen to Develop and Commercialize an ANDA Drug Product.
Akorn, Inc. and GeneraMedix Inc. Sign Commercial Manufacturing Supply Agreement.
Akorn, Inc. and FDC Limited Sign Exclusive Development and Supply Agreement for Two Ophthalmic Suspension Drug Products.
Akorn, Inc. to Present at UBS Global Generic and Specialty Pharmaceuticals Conference.
Akorn Joins NASDAQ Biotechnology Index.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles